| Ticker: | ANNX |
| Current Price: | $3.92 |
| % Daily Change: | -1.26% |
| Volume (1,000s): | 2,584.91 |
| Average Volume (1,000s): | 3,508.14 |
| Market Cap (M): | $642.26 |
| 1/2/2024 Price: | $4.84 |
| Change Since Inception: | -19.01% |
Annexon, Inc.
1400 Sierra Point Parkway
Building C Suite 200
Brisbane, CA 94005
United States
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.